REVIEW

Angiogenesis in epithelian ovarian cancer

E S Bamberger¹ and C W Perrett²

¹ Department of Biology, University of Haifa at Oranim, Tivon 36006, Israel
² Department of Obstetrics and Gynaecology, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK

Correspondence to:
Correspondence to:
Dr C W Perrett, Department of Obstetrics and Gynaecology, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK;
c.perrett{at}rfc.ucl.ac.uk

Angiogenesis, the development of new blood vessels from the existing vasculature, is an essential component of solid tumour growth and metastasis. Several angiogenic factors are expressed by many tumours, suggesting that tumours promote their own vascularisation by activating the host endothelium. This review will discuss various angiogenic stimulators and inhibitors in epithelian ovarian cancer (EOC), including vascular endothelial growth factor and platelet derived endothelial cell growth factor/thymidine phosphorylase. The analysis of tumour vascularisation by microvessel density will also be discussed and the relevance of these markers of angiogenesis in the prognosis of EOC will be assessed.

Keywords: angiogenesis; epithelian ovarian cancer; microvessel density; prognosis

Abbreviations: Ang, angiopoietin; AVD, average vessel density; bFGF, basic fibroblast growth factor; DFS, disease free survival; ELISA, enzyme linked immunosorbent assay; EOC, epithelian ovarian cancer; FIGO, International Federation of Gynaecology and Obstetrics; HVD, high vessel density; IP mice, mice bearing intraperitoneal tumours; MVD, microvessel density; OHSS, ovarian hyperstimulation syndrome; PD-ECGF, platelet derived endothelial cell growth factor; PlGF, placental growth factor; -SMA, smooth muscle antigen; TGF, transforming growth factor; TP, thymidine phosphorylase; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; VPF, vascular permeability factor; vWF, von Willebrand factor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Perotti, A., Sessa, C., Mancuso, A., Noberasco, C., Cresta, S., Locatelli, A., Carcangiu, M. L., Passera, K., Braghetti, A., Scaramuzza, D., Zanaboni, F., Fasolo, A., Capri, G., Miani, M., Peters, W. P., Gianni, L. (2009). Clinical and pharmacological phase I evaluation of ExherinTM (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Ann Oncol 20: 741-745 [Abstract] [Full Text]  
• Song, Y., Wu, J., Oyesanya, R. A., Lee, Z., Mukherjee, A., Fang, X. (2009). Sp-1 and c-Myc Mediate Lysophosphatidic Acid-Induced Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Cells via a Hypoxia-Inducible Factor-1-Independent Mechanism. Clin. Cancer Res. 15: 492-501 [Abstract] [Full Text]  
• Greenaway, J., Henkin, J., Lawler, J., Moorehead, R., Petrik, J. (2009). ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Molecular Cancer Therapeutics 8: 64-74 [Abstract] [Full Text]  
• Schultheis, A. M., Lurje, G., Rhodes, K. E., Zhang, W., Yang, D., Garcia, A. A., Morgan, R., Gandara, D., Scudder, S., Oza, A., Hirte, H., Fleming, G., Roman, L., Lenz, H.-J. (2008). Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab. Clin. Cancer Res. 14: 7554-7563 [Abstract] [Full Text]  
• Buckanovich, R. J., Sasaroli, D., O'Brien-Jenkins, A., Botbyl, J., Hammond, R., Katsaros, D., Sandaltzopoulos, R., Liotta, L. A., Gimotty, P. A., Coukos, G. (2007). Tumor Vascular Proteins As Biomarkers in Ovarian Cancer. JCO 25: 852-861 [Abstract] [Full Text]  
• DiFeo, A., Narla, G., Hirshfeld, J., Camacho-Vanegas, O., Narla, J., Rose, S. L., Kalir, T., Yao, S., Levine, A., Birrer, M. J., Bonome, T., Friedman, S. L., Buller, R. E., Martignetti, J. A. (2006). Roles of KLF6 and KLF6-SV1 in Ovarian Cancer Progression and Intraperitoneal Dissemination.. Clin. Cancer Res. 12: 3730-3739 [Abstract] [Full Text]  
• Said, N., Motamed, K. (2005). Absence of Host-Secreted Protein Acidic and Rich in Cysteine (SPARC) Augments Peritoneal Ovarian Carcinomatosis. Am. J. Pathol. 167: 1739-1752 [Abstract] [Full Text]  
• Suganuma, T., Ino, K., Shibata, K., Kajiyama, H., Nagasaka, T., Mizutani, S., Kikkawa, F. (2005). Functional Expression of the Angiotensin II Type1 Receptor in Human Ovarian Carcinoma Cells and Its Blockade Therapy Resulting in Suppression of Tumor Invasion, Angiogenesis, and Peritoneal Dissemination. Clin. Cancer Res. 11: 2686-2694 [Abstract] [Full Text]  
• Gadducci, A., Sartori, E., Landoni, F., Zola, P., Maggino, T., Maggioni, A., Cosio, S., Frassi, E., LaPresa, M. T., Fuso, L., Cristofani, R. (2005). Relationship Between Time Interval From Primary Surgery to the Start of Taxane- Plus Platinum-Based Chemotherapy and Clinical Outcome of Patients With Advanced Epithelial Ovarian Cancer: Results of a Multicenter Retrospective Italian Study. JCO 23: 751-758 [Abstract] [Full Text]  
• Fang, J., Cao, Z., Chen, Y. C., Reed, E., Jiang, B.-H. (2004). 9-{beta}-D-Arabinofuranosyl-2-fluoroadenine Inhibits Expression of Vascular Endothelial Growth Factor through Hypoxia-Inducible Factor-1 in Human Ovarian Cancer Cells. Mol. Pharmacol. 66: 178-186 [Abstract] [Full Text]